Correction to: Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer

Bautista, Rubén Rodríguez; Gómez, Alette Ortega; Hidalgo-Miranda, Alfredo; Dehesa, Alejandro Zentella; Villarreal‐Garza, Cynthia; Ávila‐Moreno, Federico; Arrieta, Óscar

doi:10.1186/s13148-018-0537-5

Cited by 16 publications

(12 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, only a few lncRNAs in TNBC have been studied in detail, indicating that lncRNAs could not only function as biomarkers for diagnosis or prognosis, but also serve as regulators in tumorigenesis, progression, and drug resistance in TNBC 19 . The aggressiveness, frequent distant metastasis, lack of targeted therapies, poor understanding of mechanism, and low response to chemotherapy of TNBC resulted in high mortality rate 20 . Thus, investigation of underlying mechanisms of lncRNAs regarding tumorigenesis and chemotherapy drug resistance of TNBC might shed lights on development of new and effective therapy strategies.…”

Section: Discussionmentioning

confidence: 99%

LncRNA DLX6-AS1 Contributes to Epithelial–Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis

Wang

Zhang

et al. 2020

Cell Transplant

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is one of the most aggressive cancer types with high recurrence, metastasis, and drug resistance. Recent studies report that long noncoding RNAs (lncRNAs)-mediated competing endogenous RNAs (ceRNA) play an important role in tumorigenesis and drug resistance of TNBC. Although elevated lncRNA DLX6 antisense RNA 1 (DLX6-AS1) has been observed to promote carcinogenesis in various cancers, the role in TNBC remained unclear. In this study, expression levels of DLX6-AS1 were increased in TNBC tissues and cell lines when compared with normal tissues or breast fibroblast cells which were determined by quantitative real-time PCR (RT-qPCR). Then, CCK-8 assay, cell colony formation assay and western blot were performed in CAL-51 cells transfected with siRNAs of DLX6-AS1 or MDA-MB-231 cells transfected with DLX6-AS1 over expression plasmids. Knock down of DLX6-AS1 inhibited cell proliferation, epithelial-mesenchymal transition (EMT), decreased expression levels of BCL2 apoptosis regulator (Bcl-2), Snail family transcriptional repressor 1 (Snail) as well as N-cadherin and decreased expression levels of cleaved caspase-3, γ-catenin as well as E-cadherin, while up regulation of DLX6-AS1 had the opposite effect. Besides, knockdown of DLX6-AS1 in CAL-51 cells or up regulation of DLX6-AS1 in MDA-MB-231 cells also decreased or increased cisplatin resistance of those cells analyzed by MTT assay. Moreover, by using dual luciferase reporter assay, RNA immunoprecipitation and RNA pull down assay, a ceRNA which was consisted by lncRNA DLX6-AS1, microRNA-199b-5p (miR-199b-5p) and paxillin (PXN) was identified. And DLX6-AS1 function through miR-199b-5p/PXN in TNBC cells. Finally, results of xenograft experiments using nude mice showed that DLX6-AS1 regulated cell proliferation, EMT and cisplatin resistance by miR-199b-5p/PXN axis in vivo. In brief, DLX6-AS1 promoted cell proliferation, EMT, and cisplatin resistance through miR-199b-5p/PXN signaling in TNBC in vitro and in vivo.

show abstract

Section: Discussionmentioning

confidence: 99%

LncRNA DLX6-AS1 Contributes to Epithelial–Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis

Wang

Zhang

et al. 2020

Cell Transplant

View full text Add to dashboard Cite

show abstract

“…Currently, new compounds with different specificity and potency are being developed, targeting different components of the PI3K/AKT/mTOR pathway (44), small molecule compounds that specifically target the mutant p53 (45,46) and compounds that inhibit tyrosine kinase enzymes, such as FLT3 (47). Mutations in DNA are not the only form of gene regulation; it is important to consider some other molecular events, including Copy Number Variation, chromosomal and epigenetic alterations, as well as the role that play micro RNAs (miRNAs) and non-coding RNA (ncRNA) (48).…”

Section: Discussionmentioning

confidence: 99%

Genetic alterations of triple negative breast cancer (TNBC) in women from Northeastern Mexico

et al. 2019

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC) is a subtype of breast cancer of heterogeneous nature that is negative for estrogen receptor (ER), progesterone receptor (PR) and growth factor human epidermal 2 (HER2) following immunohistochemical analysis. TNBC is frequently characterized by relapse and reduced survival. To date, there is no targeted therapy for this type of cancer. Chemotherapy, radiotherapy, and surgery remain as the standard treatments options. The lack of a target therapy and the heterogeneity of TNBC highlight the need to seek new therapeutic options. In this study, fresh tissue samples of TNBC were analyzed with a panel of 48 driver genes (212 amplicons) that are likely to be therapeutic targets. We found intron variants, missense, stop gained and splicing variants in TP53, PIK3CA and FLT3 genes. Interestingly, all the analyzed samples had at least two variants in the TP53 gene, one being a drug response variant, rs1042522, found in 94% of our samples. We also found seven additional variants not previously reported in the TP53 gene, to the best of our knowledge, with probable deleterious characteristics of the tumor suppressor gene. We found four genetic variants in the PIK3CA gene, including two missense variants. The rs2491231 variant in the FLT3 gene was identified in 84% (16/19) of the samples, which not yet reported for TNBC, to the best of our knowledge. In conclusion, genetic variants in TP53 were found in all TNBC tumors, with rs1042522 being the most frequent (94% of TNBC biopsies), which had not been previously reported in TNBC. Also, we found two missense variants in the PIK3CA gene. These results justify the validation of these genetic variants in a large cohort, as well as the extensive study of their impact on the prognosis and therapy management of TBNC.

show abstract

“…regulate breast cancer lung metastasis. In addition, brain metastasis has been reported to be associated with several organ-specific lncRNAs, such as lnc-BM 42 , XIST 62 , NCT02915744 III, and NCT02000882 II 150 . These data implicate potential for further development of lncRNA biomarkers for organspecific breast cancer metastases, and this warrants more attention of study.…”

Section: Prospect and Challengesmentioning

confidence: 99%

The roles of long noncoding RNAs in breast cancer metastasis

2020

View full text Add to dashboard Cite

Breast cancer is the most significant threat to female health. Breast cancer metastasis is the major cause of mortality in breast cancer patients. To fully unravel the molecular mechanisms that underlie the breast cancer cell metastasis is critical for developing strategies to improve survival and prognosis in breast cancer patients. Recent studies have revealed that the long noncoding RNAs (lncRNAs) are involved in breast cancer metastasis through a variety of molecule mechanisms, though the precise functional details of these lncRNAs are yet to be clarified. In the present review, we focus on the functions of lncRNAs in breast cancer invasion and metastasis, with particular emphasis on the functional properties, the regulatory factors, the therapeutic promise, as well as the future challenges in studying these lncRNA.

show abstract

Correction to: Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer

Cited by 16 publications

References 1 publication

LncRNA DLX6-AS1 Contributes to Epithelial–Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis

LncRNA DLX6-AS1 Contributes to Epithelial–Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis

Genetic alterations of triple negative breast cancer (TNBC) in women from Northeastern Mexico

The roles of long noncoding RNAs in breast cancer metastasis

Contact Info

Product

Resources

About